I get that but if the better immune response from using two arms is not due to chance, then it might imply, to a noob like me anyway, that the commanding officer of the body's defences is not too stressed about multiple antigen invasions at the same injection site coz the commanding officer has left entrenched more antibodies than usual in that particular site, while other antibodies move around the body telling uninformed antibodies to look out for the antigen. However, the invasion of antigens at multiple sites i.e. left AND right arm spooks the commanding officer and he has to commit even more antibodies to hang around those sites just in case there's another invasion. This leads to me wondering if that is the case, why not have the intradermal injection sites closer to where outbreaks actually occur. Why do they do deltoid area injections anyway? Is it because its closer to lymph nodes or is it simply convenience for the injector/injectee....
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
AVR
anteris technologies global corp.
Add to My Watchlist
5.16%
!
$5.91

Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-350
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.91 |
Change
0.290(5.16%) |
Mkt cap ! $91.59M |
Open | High | Low | Value | Volume |
$5.79 | $6.19 | $5.79 | $17.15K | 2.906K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38 | $5.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.10 | 170 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 38 | 5.900 |
1 | 1000 | 5.850 |
1 | 500 | 5.600 |
1 | 3045 | 5.510 |
3 | 4281 | 5.500 |
Price($) | Vol. | No. |
---|---|---|
6.300 | 100 | 1 |
6.400 | 450 | 2 |
6.550 | 1092 | 1 |
6.650 | 100 | 1 |
7.100 | 2000 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online